D. farinae Dust Mite Allergy Shots: The American HDM SCIT Guide
Dermatophagoides farinae (American house dust mite) SCIT uses an FDA-standardized 10,000 AU/mL extract and produces the largest symptom-score effect in the allergen immunotherapy literature β SMD -1.669 per Kim 2021 JACI Practice network meta-analysis of 26 RCTs. Der f 1, Der f 2, and Der f 23 sensitize 70β100% of HDM-allergic patients; 85% cross-reactivity with D.
About Curexβs SCIT program
Curexβs at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- β’ Pollens β tree, grass, weed & ragweed
- β’ Pet dander β cat & dog
- β’ Dust mites
- β’ Molds β Alternaria & mold mix
D. farinae (American House Dust Mite)is covered here for general education and may not be part of Curexβs current treatment set. Join the waitlist and our care team will help confirm your options.
D. farinae (American House Dust Mite) Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to d. farinae (american house dust mite) β rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of d. farinae (american house dust mite) allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7β10 years.
There are two evidence-based forms of d. farinae (american house dust mite) immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course β the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of d. farinae (american house dust mite) extract in a clinic, escalating over 3β6 months until a maintenance dose is reached. Continued monthly for 3β5 years. Longest clinical track record for d. farinae (american house dust mite) allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50β100+ in-person clinic visits across the full course
- Or at home with no clinic visitsβ Curexβs Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing d. farinae (american house dust mite) extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home β no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription d. farinae (american house dust mite) immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots β protocol, efficacy data, side effects, and cost. If youβd rather skip the clinic and treat d. farinae (american house dust mite) allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is D. farinae (American House Dust Mite)?
The biology, taxonomy, and clinical fingerprint of D. farinae (American House Dust Mite) β the foundation of how SCIT targets it.
Dermatophagoides farinae: the American house dust mite produces ~20 fecal pellets per day containing Der f 1 and Der f 2; a used mattress may harbor 100,000β10 million mites.
- Scientific name
- Dermatophagoides farinae
- Family
- PyroglyphidaeHouse dust mite family
- Type
- Indoor dust mite β perennial aeroallergen via fecal pellets in bedding, carpets, and upholstery
- Native to
- Continental and drier temperate indoor environments worldwide; dominant species in much of the central and western United States
- Allergen proteins
- Der f 1 (cysteine protease, 24β25 kDa, 70β100% IgE reactivity) β major allergen; shares ~80% identity with Der p 1 (major)Der f 2 (NPC2/MD-2 homolog, 14 kDa, 80β100% IgE reactivity) β major allergen; shares ~87β88% identity with Der p 2 (major)Der f 23 (peritrophin-like protein, 8 kDa) β major allergen; shares ~76% identity with Der p 23 (major)Der f 4 (alpha-amylase), Der f 7 (LPS-binding protein-like), Der f 8 (GST), Der f 10 (tropomyosin, 36β37 kDa β pan-allergen cross-reacting with shrimp and cockroach)Der f 43 β highest confirmed WHO/IUIS allergen number
- Particle size
- 10β40 ΞΌm (fecal pellets); >95% of mite allergen is fecal-pellet-associated
- Avoidance difficulty
- Nearly impossible
How D. farinae (American House Dust Mite) Allergy Presents
Symptoms by body system β useful for distinguishing D. farinae (American House Dust Mite) sensitivity from overlapping allergies and infections.
Respiratory
- Perennial allergic rhinitis: nasal congestion, sneezing, and postnasal drip year-round with seasonal peaks in autumn
- Asthma triggered by mite allergen β Sporik 1990 NEJM: all but one asthmatic child in the cohort had been exposed to >10 Β΅g Der p 1/g at age 1
- Chronic sinusitis and nasal polyps in severe perennial HDM disease
- Upper respiratory symptoms that predictably worsen in autumn as mite populations peak following summer breeding
- Nocturnal symptoms are characteristic: mites concentrate in mattresses and pillows (100,000β10 million per mattress)
Ocular
- Allergic conjunctivitis with itching, tearing, and redness β year-round in HDM-sensitized patients
- Eye symptoms often worse in the morning after prolonged mattress exposure overnight
- Periorbital edema and dark circles from chronic rubbing (allergic shiners)
Dermal
- Atopic dermatitis flares in patients with Der f 11 (paramyosin) sensitization β Der f 11 is a major allergen in atopic dermatitis specifically
- Urticaria from direct mite exposure is uncommon but documented
- Eczema exacerbation with indoor humidity increases that drive mite proliferation
Systemic
- Fatigue and sleep disruption from nocturnal nasal symptoms and asthma
- Reduced quality of life and work/school performance from perennial uncontrolled symptoms
- Shellfish reactions in Der f 10 (tropomyosin)-sensitized patients β the pan-allergen bridge to shrimp, lobster, crab, and cockroach
The Kim 2021 network meta-analysis gave us something we didn't have before β a direct comparison showing dust mite SCIT has the largest symptom-score effect size across all immunotherapy modalities with an SMD of -1.669. For patients who have already optimized their bedroom environment and are still suffering year-round, this is one of the strongest treatment recommendations I can make in all of allergy.
Where D. farinae (American House Dust Mite) Triggers Year-Round
D. farinae (American House Dust Mite) is a perennial trigger β exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundPerennial β peaks in autumn as mite populations surge after summer breeding at high humidityΒ· Year-round with autumn peak; nocturnal symptoms are characteristic due to mattress/pillow concentration
US Exposure Map
23 high-intensity statesExposure intensity by state (text version)
- ME:
- Moderate
- VT:
- Moderate
- NH:
- Moderate
- WA:
- Moderate
- MT:
- Moderate
- ND:
- Moderate
- MN:
- High
- WI:
- High
- MI:
- High
- NY:
- High
- MA:
- High
- OR:
- Moderate
- ID:
- Moderate
- WY:
- Moderate
- SD:
- Moderate
- IA:
- High
- IL:
- High
- IN:
- High
- OH:
- High
- PA:
- High
- NJ:
- High
- CT:
- High
- RI:
- High
- CA:
- Moderate
- NV:
- Moderate
- UT:
- Moderate
- CO:
- Moderate
- NE:
- High
- MO:
- High
- KY:
- High
- WV:
- High
- VA:
- High
- MD:
- High
- DE:
- High
- AZ:
- Low
- NM:
- Low
- KS:
- High
- AR:
- Moderate
- TN:
- High
- NC:
- High
- SC:
- Moderate
- OK:
- Moderate
- LA:
- Moderate
- MS:
- Moderate
- AL:
- Moderate
- GA:
- Moderate
- TX:
- Moderate
- FL:
- Moderate
- AK:
- Low
- HI:
- Low
What D. farinae (American House Dust Mite) Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
D. farinae shares ~85% IgE cross-reactivity with D. pteronyssinus via conserved Group 1 (cysteine protease) and Group 2 (NPC2/MD-2) allergens; Der f 10 (tropomyosin) creates the clinically important pan-allergen bridge to shellfish and cockroach.
Standard US dual-species vial covering D. farinae + D. pteronyssinus; maintenance targets 7β12 Β΅g Der f 1 + 7β12 Β΅g Der p 1
Der f 1 / Der p 1 share ~80% sequence identity; Der f 2 / Der p 2 share ~87β88%; Group 10 tropomyosin shares ~95%
Mite-Shellfish Cross-Reactivity via Tropomyosin
Der f 10 (tropomyosin, 36β37 kDa) shares 81% identity with shrimp Pen a 1 and ~80% with cockroach Bla g 7. HDM-sensitized individuals with Der f 10-specific IgE face elevated shellfish allergy risk β over 70% of HDM-allergic patients show IgE to shrimp in some studies. A positive Der f 10 IgE is the key biomarker.
Is SCIT Right for Your D. farinae (American House Dust Mite) Allergy?
Answer 5 questions to assess whether D. farinae allergy shots are right for your year-round dust mite symptoms.
How severe are your dust mite allergy symptoms?
The D. farinae (American House Dust Mite) SCIT Protocol
D. farinae SCIT uses FDA-standardized extract at 10,000 AU/mL; the AAAAI/ACAAI Practice Parameters recommend a maintenance dose of 7β12 Β΅g Der f 1 per injection, reached over a 3β6 month weekly build-up.
Starting at 1:100,000 dilution (Curex uses a more conservative starting concentration than the textbook 1:10,000), extract concentration is increased once weekly toward the target maintenance dose of 7β12 Β΅g Der f 1 per injection per AAAAI Practice Parameters. A 30-minute post-injection observation period is mandatory at every visit. Curex uses a conservative once-weekly build-up and does not offer rush or cluster schedules.
Maintenance injections maintain immune tolerance at the target maintenance dose; the interval is set by your prescribing allergist. The PAT study showed benefits persist 7 years after 3 years of SCIT. Most US allergists continue for at least 3β5 years; discontinuation is considered when the patient has been symptom-free for 3+ years on maintenance injections.
Disease modification after 3β5 years of SCIT typically produces lasting benefit. Retrospective cohort data (N=118,754) show AIT reduced incident asthma risk by ~40% (RR 0.60). For patients with mast cell disorder or severe allergic disease, extended treatment duration should be discussed with your allergist.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for D. farinae (American House Dust Mite) SCIT
D. farinae SCIT is backed by the strongest immunotherapy evidence in the allergy literature β a 2021 network meta-analysis of 26 RCTs gives it the largest single-modality effect size across all aeroallergen immunotherapy options.
- SCIT symptom score SMD vs placebo (largest in IT literature)85%Kim JM et al. 2021, JACI Practice 9:4450 β network meta-analysis of 26 RCTs: SMD -1.669 (95% CI -2.7 to -0.639)
- ODACTRA TCRS reduction in North American Phase III trial17%ODACTRA Study P001, 1,482 subjects β 17% TCRS improvement vs placebo; pivotal FDA approval trial
- Risk reduction in moderate/severe asthma exacerbations (HDM SLIT-tablet asthma trial P014)33%Asthma trial P014, 834 European adults β 31β34% risk reduction in moderate/severe exacerbations
- ICS dose reduction in HDM-asthmatic children with impermeable mattress encasings73%Halken S et al. 2003, JACI β 73% vs 24% achieved β₯50% ICS dose reduction with encasings (P<0.01)
D. farinae SCIT produces the largest symptom-score effect size in the allergen immunotherapy literature (SMD -1.669, Kim 2021). Combined environmental control β humidity reduction to <50% (Arlian 2001: 10-fold mite reduction), impermeable mattress encasings (Halken 2003), and hot washing at β₯60Β°C β further amplifies immunotherapy outcomes. The 2024 WAO meta-analysis found multicomponent bedroom control achieved RR 3.39 for patient-reported improvement.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
D. farinae (American House Dust Mite) SCIT Side Effects
D. farinae SCIT side effects are among the best-characterized in allergy practice due to the FDA-standardized extract and extensive safety data from decades of clinical use.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection site swelling Wheal and erythema peaking within 30 minutes and resolving within 24 hours; expected and does not require dose reduction unless >25 mm | Rate 30β50% | Mild |
Injection site itching Pruritus at site; cold compress and topical antihistamine provide relief | Rate 20β40% | Mild |
Large local reaction Swelling >25 mm or lasting >24 hours; dose reduction at next visit per AAAAI protocols | Rate 5β10% | Moderate |
Delayed local reaction Swelling appearing 6β24 hours post-injection; typically self-resolves | Rate 1β3% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis or conjunctivitis flare Sneezing, nasal congestion, or eye watering within 30 minutes; resolves with antihistamine | Rate 1β3% | Mild |
Urticaria Generalized hives requiring antihistamine and epinephrine if systemic signs present | Rate 0.1β0.5% | Mild |
Asthma exacerbation Bronchospasm during the 30-minute observation period; a baseline FEV1 β₯70% predicted is required before each injection | Rate 0.1β0.5% | Moderate |
Anaphylaxis Life-threatening systemic reaction; a prescribed epinephrine auto-injector must be confirmed on hand before the first injection, and with Curex the first injection from each new vial or concentration is supervised live in the Virtual Shot Room so your allergist can direct treatment immediately. | Rate < 0.01% per injection | Severe |
Serious systemic reactions to SCIT are uncommon, and fatal reactions are very rare in the US β they are strongly associated with protocol deviations and uncontrolled asthma rather than properly administered treatment. A baseline FEV1 β₯70% predicted is required before each injection, and patients with poorly controlled asthma should not receive SCIT on that day. Curex carries those safety safeguards into at-home care: the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, a prescribed epinephrine auto-injector is confirmed on hand, and a board-certified allergist oversees gradual, week-by-week dose escalation.
SCIT vs Alternatives for D. farinae (American House Dust Mite)
D. farinae-sensitized patients have four well-characterized options: SCIT (strongest efficacy evidence), ODACTRA SLIT-tablet (FDA-approved at-home alternative), dust mite avoidance measures, and pharmacotherapy.
| Criterion | At-home SCIT (Curex)Best | ODACTRA SLIT-tablet | Avoidance measures | Medications |
|---|---|---|---|---|
| Effectiveness | Excellent β SMD -1.669, largest in IT literature (Kim 2021) | Good β 17% TCRS reduction; 31β34% asthma exacerbation reduction | Modest alone; significant when multicomponent (WAO 2024: RR 3.39 for bedroom control) | Good for symptom suppression; no disease modification |
| 5-yr cost | $3,500β$12,000 over 5 years | Moderate β no office visit costs; tablet cost varies | Low β $50β$300 one-time for encasings | $500β$2,000/yr ongoing indefinitely |
| Duration | 3β5 years; weekly build-up then maintenance on allergist-set schedule | 3β5 years daily sublingual tablet | Ongoing β must be maintained indefinitely | Indefinite daily use required |
| Convenience | At-home weekly self-injection with Curex; no clinic visits | Home-based daily after first in-office dose | Minimal lifestyle disruption | Daily pills and sprays |
| Safety | USP <797> serum; Virtual Shot Roomβsupervised first/changed dose; epinephrine Rx on hand | Black-box warning; epinephrine Rx required | No treatment risks | Generally safe; long-term nasal steroid safety established |
| Lasting effect | Disease-modifying; 7+ years lasting benefit | Disease modification documented | Effective only while maintained | No lasting effect after stopping |
At-home SCIT (Curex)Best
ODACTRA SLIT-tablet
Avoidance measures
Medications
For patients with confirmed D. farinae sensitization and inadequate pharmacotherapy response, SCIT produces the highest degree of symptom control and the only truly disease-modifying outcome. Curex's at-home blood testing includes Der f 1, Der f 2, and Der f 23 component assays to identify specific molecular sensitization patterns before starting treatment. Curex now delivers that same subcutaneous immunotherapy as an at-home allergy shot with pricing confirmed in a current program quote: a personalized Dermatophagoides serum compounded under USP <797>, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, a prescribed epinephrine auto-injector confirmed on hand, and week-by-week dose escalation β so eligible patients get the disease-modifying modality without weekly clinic visits.
What D. farinae (American House Dust Mite) SCIT Actually Costs
Most major US insurers cover D. farinae SCIT under standard allergy benefits when ordered by a board-certified allergist and supported by diagnostic testing; prior authorization may be required. Out-of-pocket cost depends on deductible and co-insurance. ODACTRA SLIT-tablet coverage varies by insurer; a prior authorization letter is typically required.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your d. farinae (american house dust mite) allergy. Get a plan.
Take Curexβs 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you β shots or drops.
Free quiz Β· Board-certified allergists Β· 50,000+ patients treated Β· HSA/FSA eligible
D. farinae (American House Dust Mite) SCIT β Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Most patients notice meaningful symptom reduction after completing the build-up phase β approximately 3β6 months of weekly injections. Some patients experience partial relief during build-up itself. The MERIT trial showed treatment effects were measurable at 14 weeks into treatment. Maximal benefit typically develops after 12β24 months of maintenance therapy. The Kim 2021 network meta-analysis, which is the largest systematic comparison, measured symptom-score effects across 26 double-blind placebo-controlled trials, confirming sustained benefit. Patients should expect to continue for at least 3 years before considering discontinuation; most allergists recommend 3β5 years of total treatment to maximize post-treatment durability.
Antihistamines can be taken on the day of your allergy shot and may actually reduce the frequency of minor local reactions (injection site swelling and itching). However, antihistamines may mask early systemic reaction symptoms, so it is important to tell your care team if you have taken antihistamines before a dose. Self-observe for about 30 minutes after each injection regardless. Do not take antihistamines to try to prevent a systemic reaction you have previously experienced after shots β that situation requires dose adjustment and consultation with your allergist, not antihistamine pre-medication.
Not significantly β D. farinae and cockroach share tropomyosin (Der f 10 / Bla g 7) as a minor cross-reactive allergen, but the tropomyosin sensitization rate in HDM-allergic patients is only 5β18%. This shared allergen is unlikely to provide meaningful clinical cross-protection between D. farinae SCIT and cockroach allergy. If you are confirmed sensitized to both house dust mite and cockroach allergens, your allergist will typically address cockroach via integrated pest management (IPM) as the primary intervention β cockroach-specific SCIT has poor evidence per the negative CRITICAL trial (2022) β while treating your confirmed mite allergy with standardized HDM SCIT or ODACTRA.
Both use FDA-licensed Dermatophagoides extract and are supported by clinical trial evidence. D. farinae SCIT delivers the extract by subcutaneous injection weekly during build-up and monthly during maintenance; it achieves the highest effect size (SMD -1.669, Kim 2021). Traditionally those injections were given in a clinic, but Curex now delivers the same subcutaneous immunotherapy as an at-home weekly shot β a USP <797> compounded serum with the first injection from each new vial or concentration supervised live in the Virtual Shot Room and a prescribed epinephrine auto-injector confirmed on hand. A large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections the systemic reaction rate was just 0.16% per patient with no fatalities β lower than the 3%β14% typically seen with office-based shots. ODACTRA (ALK-AbellΓ³ SQ HDM SLIT-tablet) is taken daily under the tongue at home after the first in-office dose, covers both D. farinae and D. pteronyssinus in a single tablet, and is FDA-approved for ages 5β65. Its effect size is smaller than SCIT (TCRS reduction 17β22%) but it avoids injections and still produces meaningful clinical benefit, including a 31β34% reduction in moderate/severe asthma exacerbations. The choice depends on patient preference, asthma severity, and whether you prefer an injection or a sublingual tablet.
Yes β subcutaneous immunotherapy (SCIT) is approved for children, and dust mite SCIT in particular has strong pediatric evidence. The PAT study in children showed that 3 years of SCIT prevented asthma development compared to pharmacotherapy-only controls, with benefits lasting 7 years after treatment ended. The Halken 2003 JACI study showed children achieved substantially greater ICS dose reduction with combined environmental control. ODACTRA is now FDA-approved for children ages 5β11 (February 2025), and the MT-12 pediatric trial (1,460 children) showed a 22% relative reduction in TCRS. Discuss the age, severity, and commitment feasibility with a board-certified pediatric allergist to determine whether SCIT or ODACTRA is the more appropriate option for your child.
Yes, this is exactly the clinical profile where SCIT is most strongly indicated. Allergen-impermeable mattress encasings reduce allergen levels significantly but do not eliminate all mite exposure from other household reservoirs (carpets, soft furnishings, clothing, the home at large). The 2024 WAO meta-analysis found that even comprehensive multicomponent bedroom control β the best available environmental intervention β achieved RR 3.39 for patient-reported improvement, but significant symptom burden remains in most patients. SCIT addresses the immune response itself rather than just allergen levels; it reduces IgE antibody production, generates blocking IgG4 antibodies, and shifts the T-cell response from Th2 to Th1/Treg, producing changes that persist beyond the treatment period. Patients who have optimized environmental control and still experience daily symptoms are the strongest candidates for SCIT.
SCIT is safe and recommended for asthma triggered by dust mite allergy, with an important prerequisite: your asthma must be adequately controlled before each injection, defined as FEV1 β₯70% predicted on the day of the shot. Poorly controlled asthma significantly increases systemic reaction risk during SCIT build-up. The AAAAI/ACAAI Practice Parameters recommend assessment of asthma control before every injection and withholding the shot if asthma is uncontrolled. When asthma is well-controlled, dust mite SCIT may actually improve asthma control over time β the P014 asthma trial showed HDM immunotherapy reduces moderate/severe asthma exacerbations by 31β34% and reduces ICS requirements by 42% versus placebo. Discuss your asthma control status with your allergist before starting build-up.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs β including the parts that are not flattering.